Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat.

Authors :: Querol-Vilaseca M
Sirisi S
Molina-Porcel L
Molina B
Pegueroles J
Ferrer-Raventós P
Nuñez-Llaves R
Dols-Icardo O
Balasa M
Iulita MF
Blesa R
Belbin O
Clarimon J
Fortea J
Gelpi E
Sánchez-Valle R
Lleó A
Source :: Neuropathology and applied neurobiology [Neuropathol Appl Neurobiol] 2022 Apr; Vol. 48 (3), pp. e12781. Date of Electronic Publication: 2021 Dec 07.
Publication Year :: 2022
Abstract: We report the neuropathological examination of a patient with Alzheimer's disease (AD) treated for 38 months with low doses of the BACE-1 inhibitor verubecestat. Brain examination showed small plaque size, reduced dystrophic neurites around plaques and reduced synaptic-associated Aβ compared with a group of age-matched untreated sporadic AD (SAD) cases. Our findings suggest that BACE-1 inhibition has an impact on synaptic soluble Aβ accumulation and neuritic derangement in AD.<br /> (© 2021 British Neuropathological Society.)

Subjects :: Amyloid beta-Peptides metabolism
Brain pathology
Cyclic S-Oxides therapeutic use
Humans
Plaque, Amyloid drug therapy
Plaque, Amyloid pathology
Alzheimer Disease drug therapy
Alzheimer Disease pathology
Thiadiazines therapeutic use

Full Text Access

Tools